The C-terminal SH3 domain contributes to the intramolecular inhibition of Vav family proteins

Science Signaling

Volumn 7, Issue 321, 2014, Pages

  Barreira, María ^a,b   Fabbiano, Salvatore ^a,b   Couceiro, José R ^a,b   Torreira, Eva ^c   Martínez Torrecuadrada, Jorge L ^d   Montoya, Guillermo ^d   Llorca, Oscar ^c   Bustelo, Xosé R ^a,b  

^a Centro de Investigacion del Cancer   (Spain)

^b Salamanca Spain   (Spain)

^c CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE EXCHANGE FACTOR; PLECKSTRIN; PROTEIN SH3; TYROSINE; VAV PROTEIN; GUANOSINE TRIPHOSPHATASE; PROLINE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; 3T3 CELL LINE; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; ENZYME ACTIVE SITE; ESCHERICHIA COLI; JURKAT CELL LINE; METABOLISM; MOUSE; MULTIGENE FAMILY; PHOSPHORYLATION; THREE DIMENSIONAL IMAGING;

ANIMALS; CATALYTIC DOMAIN; CERCOPITHECUS AETHIOPS; COS CELLS; DROSOPHILA MELANOGASTER; ESCHERICHIA COLI; GTP PHOSPHOHYDROLASES; HUMANS; IMAGING, THREE-DIMENSIONAL; JURKAT CELLS; MICE; MULTIGENE FAMILY; NIH 3T3 CELLS; PHOSPHORYLATION; PROLINE; PROTO-ONCOGENE PROTEINS C-VAV; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TYROSINE;

EID: 84899094478     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004993     Document Type: Article

References (65)

1. X. R. Bustelo, M. Barbacid, Tyrosine phosphorylation of the vav proto-oncogene product in activated b cells. Science 256, 1196-1199 (1992).
2. X. R. Bustelo, J. A. Ledbetter, M. Barbacid, Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates. Nature 356, 68-71 (1992).
3. M. Turner, D. D. Billadeau, VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2, 476-486 (2002).
4. X. R. Bustelo, in Encyclopedia of Signaling Molecules, S. Choy, Ed. (Springer, New York, 2012), pp. 1963-1976.
5. X. R. Bustelo, Regulatory and signaling properties of the vav family. Mol. Cell. Biol. 20, 1461-1477 (2000).
6. K. E. Schuebel, N. Movilla, J. L. Rosa, X. R. Bustelo, Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 17, 6608-6621 (1998).
7. N. Movilla, X. R. Bustelo, Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell. Biol. 19, 7870-7885 (1999).
8. P. Crespo, K. E. Schuebel, A. A. Ostrom, J. S. Gutkind, X. R. Bustelo, Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385, 169-172 (1997).
9. V. L. Tybulewicz, Vav-family proteins in T-cell signalling. Curr. Opin. Immunol. 17, 267- 274 (2005).
10. R. Faccio, S. L. Teitelbaum, K. Fujikawa, J. Chappel, A. Zallone, V. L. Tybulewicz, F. P. Ross, W. Swat, Vav3 regulates osteoclast function and bone mass. Nat. Med. 11, 284-290 (2005).
11. V. Sauzeau, M. A. Sevilla, J. V. Rivas-Elena, E. de Alava, M. J. Montero, J. M. López-Novoa, X. R. Bustelo, Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat. Med. 12, 841-845 (2006).
12. V. Sauzeau, M. Jerkic, J. M. López-Novoa, X. R. Bustelo, Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol. Biol. Cell 18, 943-952 (2007).
13. V. Sauzeau, J. A. C. Horta-Junior, A. S. Riolobos, G. Fernández, M. A. Sevilla, D. E. López, M. J. Montero, B. Rico, X. R. Bustelo, Vav3 is involved in GABAergic axon guidance events important for the proper function of brainstem neurons controlling cardiovascular, respiratory, and renal parameters. Mol. Biol. Cell 21, 4251-4263 (2010).
14. V. Sauzeau, M. A. Sevilla, M. J. Montero, X. R. Bustelo, The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J. Clin. Invest. 120, 315-330 (2010).
15. C. Quevedo, V. Sauzeau, M. Menacho-Márquez, A. Castro-Castro, X. R. Bustelo, Vav3-deficient mice exhibit a transient delay in cerebellar development. Mol. Biol. Cell 21, 1125-1139 (2010).
16. C.W. Cowan, Y. R. Shao, M. Sahin, S. M. Shamah, M. Z. Lin, P. L. Greer, S. Gao, E. C. Griffith, J. S. Brugge, M. E. Greenberg, Vav family GEFs link activated Ephs to endocytosis and axon guidance. Neuron 46, 205-217 (2005).
17. C. F. Hale, K. C. Dietz, J. A. Varela, C. B. Wood, B. C. Zirlin, L. S. Leverich, R. W. Greene, C. W. Cowan, Essential role for Vav guanine nucleotide exchange factors in brain-derived neurotrophic factor-induced dendritic spine growth and synapse plasticity. J. Neurosci. 31, 12426-12436 (2011).
18. K. R. Norman, R. T. Fazzio, J. E.Mellem, M. V. Espelt, K. Strange, M. C. Beckerle, A. V. Maricq, The Rho/Rac-family guanine nucleotide exchange factor VAV-1 regulates rhythmic behaviors in C. elegans. Cell 123, 119-132 (2005).
19. C. Citterio, M. Menacho-Márquez, R. García-Escudero, R. M. Larive, O. Barreiro, F. Sánchez-Madrid, J. M. Paramio, X. R. Bustelo, The Rho exchange factors Vav2 and Vav3 control a lung metastasis-specific transcriptional program in breast cancer cells. Sci. Signal. 5, ra71 (2012).
20. K. H. Chang, A. Sanchez-Aguilera, S. Shen, A. Sengupta, M. N. Madhu, A. M. Ficker, S. K. Dunn, A. M. Kuenzi, J. L. Arnett, R. A. Santho, X. Agirre, J. P. Perentesis, M.W. Deininger, Y. Zheng, X. R. Bustelo, D. A. Williams, J. A. Cancelas, Vav3 collaborates with p190- BCR-ABL in lymphoid progenitor leukemogenesis, proliferation and survival. Blood 120, 800-811 (2012).
21. S. Katzav, D. Martin-Zanca, M. Barbacid, vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J. 8, 2283-2290 (1989).
22. M. E. Fernandez-Zapico, N. C. Gonzalez-Paz, E.Weiss, D. N. Savoy, J. R. Molina, R. Fonseca, T. C. Smyrk, S. T. Chari, R. Urrutia, D. D. Billadeau, Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7, 39-49 (2005).
23. M. Menacho-Márquez, R. García-Escudero, V. Ojeda, A. Abad, P. Delgado, C. Costa, S. Ruiz, B. Alarcón, J. M. Paramio, X. R. Bustelo, The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLOS Biol. 11, e1001615 (2013).
24. H. Martin, R. S. Mali, P. Ma, A. Chatterjee, B. Ramdas, E. Sims, V. Munugalavadla, J. Ghosh, R. R. Mattingly, V. Visconte, R. V. Tiu, C. P. Vlaar, S. Dharmawardhane, R. Kapur, Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J. Clin. Invest. 123, 4449-4463 (2013).
25. M. Menacho-Márquez, R. Nogueiras, S. Fabbiano, V. Sauzeau, O. Al-Massadi, C. Diéguez, X. R. Bustelo, Chronic sympathoexcitation through loss of Vav3, a Rac1 activator, results in divergent effects on metabolic syndrome and obesity depending on diet. Cell Metab. 18, 199-211 (2013).
26. M. Jagodic, C. Colacios, R. Nohra, A. S. Dejean, A. D. Beyeen, M. Khademi, A. Casemayou, L. Lamouroux, C. Duthoit, O. Papapietro, L. Sjöholm, I. Bernard, D. Lagrange, I. Dahlman, F. Lundmark, A. B. Oturai, H. B. Soendergaard, A. Kemppinen, J. Saarela, P. J. Tienari, H. F. Harbo, A. Spurkland, S. V. Ramagopalan, D. A. Sadovnick, G. C. Ebers, M. Seddighzadeh, L. Klareskog, L. Alfredsson, L. Padyukov, J. Hillert, M. Clanet, G. Edan, B. Fontaine, G. J. Fournié, I. Kockum, A. Saoudi, T. Olsson, A role for VAV1 in experimental auto-immune encephalomyelitis and multiple sclerosis. Sci. Transl. Med. 1, 10ra21 (2009).
27. M. López-Lago, H. Lee, C. Cruz, N. Movilla, X. R. Bustelo, Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol. Cell. Biol. 20, 1678-1691 (2000).
28. J. L. Zugaza, M. A. López-Lago, M. J. Caloca, M. Dosil, N. Movilla, X. R. Bustelo, Structural determinants for the biological activity of Vav proteins. J. Biol. Chem. 277, 45377-45392 (2002).
29. J. Rapley, V. L. Tybulewicz, K. Rittinger, Crucial structural role for the PH and C1 domains of the Vav1 exchange factor. EMBO Rep. 9, 655-661 (2008).
30. J. E. Chrencik, A. Brooun, H. Zhang, I. I. Mathews, G. L. Hura, S. A. Foster, J. J. Perry, M. Streiff, P. Ramage, H. Widmer, G. M. Bokoch, J. A. Tainer, G. Weckbecker, P. Kuhn, Structural basis of guanine nucleotide exchange mediated by the T-cell essential Vav1. J. Mol. Biol. 380, 828-843 (2008).
31. B. Yu, I. R. Martins, P. Li, G. K. Amarasinghe, J. Umetani, M. E. Fernandez-Zapico, D. D. Billadeau, M. Machius, D. R. Tomchick, M. K. Rosen, Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 140, 246-256 (2010).
32. J. Wu, S. Katzav, A. Weiss, A functional T-cell receptor signaling pathway is required for p95vav activity. Mol. Cell. Biol. 15, 4337-4346 (1995).
33. F. Macian, NFAT proteins: Key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472-484 (2005).
34. O. Ksionda, A. Saveliev, R. Köchl, J. Rapley, M. Faroudi, J. E. Smith-Garvin, C. Wülfing, K. Rittinger, T. Carter, V. L. Tybulewicz, Mechanism and function of Vav1 localisation in TCR signalling. J. Cell Sci. 125, 5302-5314 (2012).
35. Z. Zhou, J. Yin, Z. Dou, J. Tang, C. Zhang, Y. Cao, The calponin homology domain of Vav1 associates with calmodulin and is prerequisite to T cell antigen receptor-induced calcium release in Jurkat T lymphocytes. J. Biol. Chem. 282, 23737-23744 (2007).
36. M. Groysman, M. Nagano, B. Shaanan, S. Katzav, Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Oncogene 17, 1597-1606 (1998).
37. J. R. Couceiro, M. D. Martín-Bermudo, X. R. Bustelo, Phylogenetic conservation of the regulatory and functional properties of the Vav oncoprotein family. Exp. Cell Res. 308, 364-380 (2005).
38. G. M. Doody, D. D. Billadeau, E. Clayton, A. Hutchings, R. Berland, S. McAdam, P. J. Leibson, M. Turner, Vav-2 controls NFAT-dependent transcription in B- but not T-lymphocytes. EMBO J. 19, 6173-6184 (2000).
39. R. García-Mata, K. Wennerberg, W. T. Arthur, N. K. Noren, S. M. Ellerbroek, K. Burridge, Analysis of activated GAPs and GEFs in cell lysates. Methods Enzymol. 406, 425-437 (2006).
40. S. Maignan, J. P. Guilloteau, N. Fromage, B. Arnoux, J. Becquart, A. Ducruix, Crystal structure of the mammalian Grb2 adaptor. Science 268, 291-293 (1995).
41. S. Yuzawa, M. Yokochi, H. Hatanaka, K. Ogura, M. Kataoka, K. Miura, V. Mandiyan, J. Schlessinger, F. Inagaki, Solution structure of Grb2 reveals extensive flexibility necessary for target recognition. J. Mol. Biol. 306, 527-537 (2001).
42. J. A. Wells, Systematic mutational analyses of protein-protein interfaces. Methods Enzymol. 202, 390-411 (1991).
43. X. R. Bustelo, K. L. Suen, W. M. Michael, G. Dreyfuss, M. Barbacid, Association of the vav proto-oncogene product with poly(rC)-specific RNA-binding proteins. Mol. Cell. Biol. 15, 1324-1332 (1995).
44. vav/heterogeneous ribonucleoprotein K interaction. J. Biol. Chem. 269, 20225-20228 (1994).
45. X. R. Bustelo, Regulation of Vav proteins by intramolecular events. Front. Biosci. 7, d24-d30 (2002).
46. B. Aghazadeh, W. E. Lowry, X. Y. Huang, M. K. Rosen, Structural basis for relief of auto-inhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 102, 625-633 (2000).
47. C. Kintscher, S. Wuertenberger, R. Eylenstein, T. Uhlendorf, Y. Groemping, Autoinhibition of GEF activity in intersectin 1 is mediated by the short SH3-DH domain linker. Protein Sci. 19, 2164-2174 (2010).
48. K. F. Ahmad, W. A. Lim, The minimal autoinhibited unit of the guanine nucleotide exchange factor intersectin. PLOS One 5, e11291 (2010).
49. M. R. Schiller, K. Chakrabarti, G. F. King, N. I. Schiller, B. A. Eipper, M. W. Maciejewski, Regulation of RhoGEF activity by intramolecular and intermolecular SH3 domain interactions. J. Biol. Chem. 281, 18774-18786 (2006).
50. N. Mitin, L. Betts, M. E. Yohe, C. J. Der, J. Sondek, K. L. Rossman, Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nat. Struct. Mol. Biol. 14, 814-823 (2007).
51. K. Murayama, M. Shirouzu, Y. Kawasaki, M. Kato-Murayama, K. Hanawa-Suetsugu, A. Sakamoto, Y. Katsura, A. Suenaga, M. Toyama, T. Terada, M. Taiji, T. Akiyama, S. Yokoyama, Crystal structure of the Rac activator, Asef, reveals its autoinhibitory mechanism. J. Biol. Chem. 282, 4238-4242 (2007).
52. M. E. Yohe, K. Rossman, J. Sondek, Role of the C-terminal SH3 domain and N-terminal tyrosine phosphorylation in regulation of Tim and related Dbl-family proteins. Biochemistry 47, 6827-6839 (2008).
53. O. T. Fackler, W. Luo, M. Geyer, A. S. Alberts, B. M. Peterlin, Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol. Cell 3, 729-739 (1999).
54. L. Rodrigues, M. Pires de Miranda, M. J. Caloca, X. R. Bustelo, J. P. Simas, Activation of Vav by the gammaherpesvirus M2 protein contributes to the establishment of viral latency in B lymphocytes. J. Virol. 80, 6123-6135 (2006).
55. A. Castro-Castro, V. Ojeda, M. Barreira, V. Sauzeau, I. Navarro-Lérida, O. Muriel, J. R. Couceiro, F. X. Pimentel- Muíños, M. A. Del Pozo, X. R. Bustelo, Coronin 1A promotes a cytoskeletal-based feedback loop that facilitates Rac1 translocation and activation. EMBO J. 30, 3913-3927 (2011).
56. M. J. Caloca, J. L. Zugaza, X. R. Bustelo, Mechanistic analysis of the amplification and diversification events induced by Vav proteins in B-lymphocytes. J. Biol. Chem. 283, 36454-36464 (2008).
57. J. Coppola, S. Bryant, T. Koda, D. Conway, M. Barbacid, Mechanism of activation of the vav protooncogene. Cell Growth Differ. 2, 95-105 (1991).
58. S. Ruiz, E. Santos, X. R. Bustelo, RasGRF2, a guanosine nucleotide exchange factor for Ras GTPases, participates in T-cell signaling responses. Mol. Cell. Biol. 27, 8127-8142 (2007).
59. N. Movilla, M. Dosil, Y. Zheng, X. R. Bustelo, How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42. Oncogene 20, 8057-8065 (2001).
60. A. J. van der Eb, F. L. Graham, Assay of transforming activity of tumor virus DNA. Methods Enzymol. 65, 826-839 (1980).
61. H. Luthman, G. Magnusson, High efficiency polyoma DNA transfection of chloroquine treated cells. Nucleic Acids Res. 11, 1295-1308 (1983).
62. J. A. Mindell, N. Grigorieff, Accurate determination of local defocus and specimen tilt in electron microscopy. J. Struct. Biol. 142, 334-347 (2003).
63. J. B. Heymann, D. M. Belnap, Bsoft: Image processing and molecular modeling for electron microscopy. J. Struct. Biol. 157, 3-18 (2007).
64. S. J. Ludtke, P. R. Baldwin, W. Chiu, EMAN: Semiautomated software for high-resolution single-particle reconstructions. J. Struct. Biol. 128, 82-97 (1999).
65. L. A. Kelley, M. J. Sternberg, Protein structure prediction on the Web: A case study using the Phyre server. Nat. Protoc. 4, 363-371 (2009).